1. Home
  2. IVDA vs GRI Comparison

IVDA vs GRI Comparison

Compare IVDA & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iveda Solutions Inc.

IVDA

Iveda Solutions Inc.

HOLD

Current Price

$1.04

Market Cap

4.5M

Sector

Technology

ML Signal

HOLD

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$0.52

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IVDA
GRI
Founded
2003
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5M
4.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IVDA
GRI
Price
$1.04
$0.52
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$23.00
AVG Volume (30 Days)
9.2M
1.2M
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,395,926.00
N/A
Revenue This Year
$340.48
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
20.56
N/A
52 Week Low
$0.61
$0.50
52 Week High
$8.05
$16.66

Technical Indicators

Market Signals
Indicator
IVDA
GRI
Relative Strength Index (RSI) 47.59 22.14
Support Level $1.11 $0.50
Resistance Level $1.37 $2.17
Average True Range (ATR) 0.16 0.19
MACD 0.01 -0.16
Stochastic Oscillator 33.15 0.85

Price Performance

Historical Comparison
IVDA
GRI

About IVDA Iveda Solutions Inc.

Iveda Solutions Inc offers smart city technologies globally, offering advanced AI-driven video surveillance solutions and a robust suite of Internet of Things (IoT) platforms that power digital transformation for cities and commercial clients worldwide. The smart cities market, as well as the AI and IoT segments, are poised for significant growth in the coming years. The company offers AI-intelligent video search, smart utility, smart sensors, gateways, and trackers, and IoT platforms (Products).

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: